Ph-Positive Acute Lymphoblastic Leukemia: Dasatinib/Blinatumomab Effective in Phase 2

Positive survival outcomes were observed in patients with Philadelphia chromosome (Ph)-positive acute lymphoblastic leukemia (ALL) when treated with dasatinib followed by blinatumomab in in a phase 2 study now published in the New England Journal of Medicine. For the trial, adults with newly diagnosed Ph-positive ALL were given a seven-day prephase treatment with a glucocorticoid prior to the first administration of dasatinib in a 140 mg dose. Glucocorticoids were continued for 24 more days...

Continue reading

Dasatinib Improves Outcomes in Patients With Chronic Myeloid Leukemia and High BMI

According to a subgroup analysis of a phase 3 study, dasatinib produces significantly faster and more durable responses compared with imatinib in patients with chronic phase chronic myeloid leukemia (CML) and a high body mass index (BMI). Previous studies have reported that patients with a high BMI, defined as over 25 kg/m2, are at an increased risk of not only developing CML but also of experiencing poorer outcomes when treated with first-line tyrosine kinase inhibitors (TKIs) such as imatinib....

Continue reading

Copyright © 2022 Oncology Data Advisor. All rights reserved.